ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Has Average Price Target of $98.00 According to Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has earned a consensus recommendation of “Hold” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $99.60.

A number of brokerages recently weighed in on ANIP. Oppenheimer began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They set a “market perform” rating and a $85.00 price objective on the stock. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 target price for the company. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Canaccord Genuity Group dropped their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Finally, Guggenheim reduced their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday, August 10th.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, CEO Nikhil Lalwani sold 5,400 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $71.00, for a total transaction of $383,400.00. Following the sale, the chief executive officer owned 339,089 shares of the company’s stock, valued at $24,075,319. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $77.00, for a total value of $243,474.00. Following the completion of the sale, the senior vice president owned 75,534 shares of the company’s stock, valued at $5,816,118. This trade represents a 4.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 25,012 shares of company stock valued at $1,861,085. 8.10% of the stock is currently owned by company insiders.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. KBC Group NV bought a new position in ANI Pharmaceuticals during the first quarter valued at about $28,000. Versant Capital Management Inc raised its position in ANI Pharmaceuticals by 103.3% in the third quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 217 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in ANI Pharmaceuticals in the second quarter worth about $76,000. State of Wyoming bought a new stake in ANI Pharmaceuticals in the second quarter worth about $86,000. Finally, GAMMA Investing LLC lifted its holdings in ANI Pharmaceuticals by 13.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,783 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 211 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Up 2.7%

Shares of NASDAQ:ANIP opened at $73.89 on Thursday. The company’s fifty day moving average is $74.41 and its two-hundred day moving average is $78.03. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. ANI Pharmaceuticals has a 1-year low of $69.58 and a 1-year high of $97.00. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of 15.92, a price-to-earnings-growth ratio of 2.38 and a beta of 0.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same period in the previous year, the business posted $1.80 EPS. The company’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts anticipate that ANI Pharmaceuticals will post 7.76 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.

ANI’s portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products.